Prescription RequiredSOFOSBUVIR 400 mg + VELPATASVIR 100 mg is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection in adults. This fixed-dose combination contains sofosbuvir, an NS5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor, providing effective treatment against all major hepatitis C genotypes. When taken as prescribed, it can help achieve a sustained virologic response (SVR), which is considered a cure for many patients.
| Generic name | SOFOSBUVIR/VELPATASVIR |
| Strength | 400 mg + 100 mg |
| Manufacturer | Cipla |
| Package size | 28 Tablets |
| Used for | Chronic hepatitis C virus (HCV) infection |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Sofosbuvir and Velpatasvir work by targeting two essential proteins required for hepatitis C virus replication. Sofosbuvir inhibits the NS5B RNA polymerase, preventing the virus from making new genetic material, while Velpatasvir blocks the NS5A protein, which is necessary for viral replication and assembly. Together, they stop the virus from multiplying and help clear the infection.
